London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
[img]http://phpstack-911252-3168991.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=b84e2215-c8f1-44ea-8821-68c4a41362ab&size=3[/img]
[img]http://phpstack-911252-3168991.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=7f3b1a4d-98f0-449f-802e-4227efcb87b8&size=3[/img]